UVA-1 Phototherapy Expands Treatment Options

Ultraviolet (UV) phototherapy, in one form or another, has been used by the medical community since the 1950’s to treat a variety of skin conditions, with the most common being psoriasis, vitiligo and eczema.  In the last decade, advancements in medical device technology have made phototherapy treatments even more effective and accessible for these patients, as well as others suffering from more complex conditions.  Over the last decade, Narrowband UVB ((NBUVB) 311-312 nm) has been the clinical standard for treating common dermatologic conditions, but UVA-1 (340-400 nm) advancements have expanded treatment options for a wider group of patients. Unlike UVA (320-400 nm), UVA-1 does not require the use of a combination medication (psoralen), which eases the burden on both the clinic and patient alike.

UVA-1 works by penetrating deeper into the dermis than BBUVB (280-315 nm), NBUVB (311-312 nm) or UVA (320-400 nm), reaching the inflammatory cells that spur many chronic skin conditions.  UVA-1 can be used in the treatment of certain autoimmune connective tissue disorders, such as lupus, along with other complex conditions including cutaneous T cell lymphoma, vitiligo, morphea, graft-versus-host disease, and systemic sclerosis.  Current research continues to point to additional treatment indications specific to medium to high dose UVA-1 phototherapy and overall effectiveness.

Typically found in larger medical institutions and teaching facilities, Daavlin’s ML24000 high-intensity, high-output UVA1 unit is the only full-body unit in the North American market that delivers pure UVA-1.  A proprietary combination of high-intensity discharge lamps and filters eliminates UVB and UVC wavelengths while delivering high dose protocols in a fraction of the time versus competitive fluorescent units.

Low output fluorescent UVA-1 units cannot deliver an effective high dose without UVB induced erythema, making the ML24000 the safest, most advanced, UVA-1 phototherapy unit on the market.  For more information on our ML24000, please click here or email clinical@daavlin.com.